Leukemias

Share

Program Content

Activities

RATIFY 10-Yr Follow-Up
CALGB 10603/RATIFY: 10-Yr Follow-up of Midostaurin vs Placebo Combined With Intensive CT for Newly Diagnosed FLT3-Mutant AML 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2024

Expires: December 09, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation